Clinical Trials

Phase 2/3 Active not recruiting

Brenner Tumor, Fallopian Tube Neoplasms

NCT02839707 2026-04-13

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

444 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03587311 2026-04-13

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

96 enrolled

Fallopian Tube Endometrioid Adenocarcinoma

NCT03694262 2026-04-13

EndoBARR

Phase 2 Completed

30 enrolled 7 charts

Endometrial Neoplasms

NCT05183984 2026-04-13

NIRVANA-1

390 enrolled

Ovarian Neoplasms

NCT05739981 2026-04-13

MRD

30 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07198074 2026-04-13

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

255 enrolled

Phase 2 Not yet recruiting

Endometrial Neoplasms

NCT07504588 2026-04-13

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

87 enrolled

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

NCT05919264 2026-04-09

FOG-001 in Locally Advanced or Metastatic Solid Tumors

CNSGastrointestinalGenitourinaryGynecologicSarcoma

595 enrolled

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

NCT07216703 2026-04-09

TroFuse-036

1,023 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT06787612 2026-04-08

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

220 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07225270 2026-04-08

RAINFOL-04

528 enrolled

Ovarian Neoplasms

NCT04516447 2026-04-07

MUIR

172 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT05579366 2026-04-07

RAINFOL-01

BreastGynecologicOther solid neoplasmThoracic

764 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04938583 2026-04-06

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Phase 1/2 Active not recruiting

54 enrolled

Ovarian Neoplasms

NCT07024784 2026-04-06

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

377 enrolled

Fallopian Tube Neoplasms, Neoplasms

NCT02873962 2026-04-01

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

72 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04486352 2026-04-01

EndoMAP

148 enrolled

Endometrial Neoplasms

NCT06843447 2026-03-27

MK-5909-003

280 enrolled

Phase 2 Not yet recruiting

Ovarian Cancer Recurrent

NCT07497074 2026-03-27

JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer

78 enrolled

Uterine Cervical Neoplasms

NCT06580314 2026-03-24

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

880 enrolled

Ovarian Neoplasms

NCT04919629 2026-03-23

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

60 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07213804 2026-03-20

FRAmework-01

1,080 enrolled

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05489211 2026-03-19

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

GastrointestinalGynecologic

454 enrolled

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

186 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT05231122 2026-03-16

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

80 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Phase 2/3 Recruiting

120 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07472153 2026-03-16

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

Phase 2/3 Recruiting

120 enrolled

Uterine Cervical Neoplasms

NCT07470853 2026-03-13

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

265 enrolled

Ovarian Neoplasms, Endometrial Neoplasms

NCT04931342 2026-03-10

BOUQUET

176 enrolled

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

643 enrolled 17 charts 3 FDA

Phase 1/2 Not yet recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

626 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT06819007 2026-03-05

DO-01

582 enrolled

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT06083844 2026-03-04

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

20 enrolled

Ovarian Neoplasms

NCT05797168 2026-03-02

FONTANA

506 enrolled

GynecologicThoracic

Adenocarcinoma of Lung, Ovarian Neoplasms, Endometrial Neoplasms

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

134 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT05445778 2026-02-23

GLORIOSA

520 enrolled

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT02884648 2026-02-06

Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery

35 enrolled

617 enrolled 29 charts 2 FDA

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

Phase 3 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT06469281 2026-02-03

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

90 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02734004 2026-01-29

MEDIOLA

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT07370818 2026-01-27

To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

Phase 2 Not yet recruiting

81 enrolled

Ovarian Neoplasms

NCT05636111 2026-01-22

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

34 enrolled